Drugs / SBS-147
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07335913 | Jan 2026 → Jan 2027 expected | — | Sparian Biosciences, Inc | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-04-09 | Sparian Biosciences, Inc | Sparian Biosciences Announces Initiation of Phase 1 Clinical Trial of SBS-147 Next Generation Arylepoxamide Agonist for the Treatment of Pain Funded by a $15M NIH Grant sparianbiosciences.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBS-147 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07335913 ↗ |
| Route | Oral | “ORALLY ADMINISTERED SBS-147” NCT07335913 ↗ |